GlassScriptPhysician profile
Steven Goldberg
NPI 1205839255
$77,991.46
in general payments reported to CMS, 2019-2025
30 companies · $902 in 2025
The $902 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,804 · 2020: $13K · 2021: $24K · 2022: $16K · 2023: $8,650 · 2024: $11K · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $3,459 · Consulting Fee: $1,860 · Education: $32.27 · Travel and Lodging: $31.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,430.00 |
| Food and Beverage | $3,458.57 |
| Consulting Fee | $1,860.00 |
| Education | $32.27 |
| Travel and Lodging | $31.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $34,848.62 | 2019-2024 | Jardiance |
| Esperion Therapeutics, INC. | $19,481.40 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $10,378.66 | 2019-2024 | Lokelma |
| Lilly USA, LLC | $5,948.15 | 2020-2024 | Jardiance |
| Abbott Laboratories | $925.80 | 2019-2025 | Cardiomems, Navitor |
| Boston Scientific Corporation | $894.94 | 2019-2024 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $763.02 | 2020-2024 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $690.67 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $562.06 | 2019-2025 | |
| Pfizer INC. | $479.53 | 2019-2025 | |
| Medtronic, INC. | $441.03 | 2021-2023 | Cobalt Dr Mri Surescan, Micra |
| Heartflow, INC. | $427.43 | 2024-2025 | |
| Novo Nordisk INC | $332.90 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Edwards Lifesciences Corporation | $319.09 | 2025 | Sapien 3 Ultra Resilia |
| Amgen INC. | $281.28 | 2019-2025 | Repatha, Repatha |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $242.61 | 2022-2024 | Barostim Neo System |
| Biohaven Pharmaceuticals, INC. | $212.80 | 2021 | |
| Alnylam Pharmaceuticals INC. | $122.83 | 2023 | Amvuttra |
| Abbvie INC. | $119.97 | 2020-2022 | |
| Glaxosmithkline, LLC. | $115.56 | 2020 | |
| Merck Sharp & Dohme LLC | $111.22 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $67.54 | 2019-2022 | |
| Althera Pharmaceuticals LLC | $59.03 | 2021 | |
| Sanofi-Aventis U.S. LLC | $46.49 | 2019 | |
| Bardy Diagnostics, INC. | $38.75 | 2022 | |
| Terumo Medical Corporation | $38.16 | 2023 | Azur Cx Detachable |
| Coala Life INC | $23.73 | 2021 | |
| Lundbeck LLC | $12.66 | 2019 | |
| Vivaquant INC, Dba Rhythm Express | $5.53 | 2025 | Rhythm Express |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Goldberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.